{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-022559","form_type":"8-K","ticker":"FDMT","cik":"0001650648","company_name":"4D Molecular Therapeutics, Inc.","filed_at":"2026-01-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.763433+00:00","generated_at":"2026-05-16T07:57:27.493722+00:00","sec_items":["3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"4D Molecular Therapeutics exchanges 6.6M shares for pre-funded warrants with RA Capital and BVF","bullets":["RA Capital exchanged 4,850,000 shares for a warrant to acquire 4,850,000 shares.","BVF exchanged 1,750,000 shares for a warrant to acquire 1,750,000 shares.","Post-exchange shares outstanding as of Jan 23, 2026: 51,007,874; warrants exercisable for 16,935,665 total shares.","Warrants have $0.0001 exercise price, no expiration, and 4.99%/9.99% beneficial ownership blocker.","Issued in reliance on Section 3(a)(9) exemption from registration."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-022559","json":"https://secwatch.observer/filing/0001193125-26-022559.json","markdown":"https://secwatch.observer/filing/0001193125-26-022559.md","text":"https://secwatch.observer/filing/0001193125-26-022559.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650648/000119312526022559/0001193125-26-022559-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650648/000119312526022559/fdmt-20260122.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T07:57:27.493722+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}